Did you know? You can suggest edits to improve this peptide information.
Overview
What is Tesamorelin?
Tesamorelin is an FDA-approved synthetic growth hormone-releasing hormone (GHRH) analog designed for treating HIV-associated lipodystrophy. This 44-amino acid peptide with a trans-3-hexenoic acid modification selectively reduces visceral adipose tissue while preserving subcutaneous fat, making it unique among growth hormone therapies.
Key Benefits
FDA-approved formulation, selective visceral fat targeting, proven clinical efficacy, standardized dosing
Mechanism of Action
Subcutaneous injection provides optimal bioavailability for GHRH receptor binding and pulsatile GH release stimulation
Molecular Information
Weight
5,135.9 Da
Length
44 amino acids
Type
GHRH analog
Amino Acid Sequence:
His-Ala-Asp-Gly-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu
* Modified with trans-3-hexenoic acid at N-terminus for enhanced stability
Pharmacokinetics
Research Indications
HIV-Associated Lipodystrophy
FDA-approved indication showing 15-20% visceral fat reduction in clinical trials
Selective Visceral Fat Targeting
Unique mechanism spares subcutaneous fat while reducing harmful visceral adiposity
Sustained Fat Loss
Maintained weight loss with continuous treatment over 52+ weeks in clinical studies
Research Protocols
Disclaimer
These are commonly discussed research protocols and not medical advice. Consult a healthcare provider before use.
Timing
Evening injection aligns with natural growth hormone circadian rhythm. Take after dinner but before bedtime for optimal efficacy.
Peptide Interactions
How to Reconstitute
Important
Always use bacteriostatic water (BAC). Sterile technique is essential.
Remove vial from refrigerator (powder should be stored at 2-8°C) and allow to reach room temperature
Egrifta SV: Add 0.5 mL sterile water to 2 mg vial
Egrifta WR: Add 1.3 mL bacteriostatic water to 11.6 mg vial
Gently swirl to dissolve - do not shake vigorously to prevent protein denaturation
Solution should be clear and colorless - do not use if cloudy or contains particles
Withdraw appropriate dose (typically 0.35 mL for 1.4 mg from SV preparation)
Inject subcutaneously in abdomen, rotating sites to prevent lipodystrophy
SV: Use immediately after mixing, discard any remaining solution. WR: Store at room temperature (20-25°C) for up to 7 days — do NOT refrigerate as it may cause precipitation
Quality Indicators
FDA-approved formulations
Egrifta SV or Egrifta WR from licensed pharmacy with proper documentation
White crystalline powder
Lyophilized powder should be white, uniform, and cake-like in appearance
Clear reconstituted solution
After mixing, solution should be clear and colorless without particles
Proper packaging integrity
Sealed vials with intact rubber stoppers and aluminum seals
Discolored or cloudy solution
Any yellow/brown color or cloudiness indicates degradation or contamination
Visible particles or precipitate
Particles indicate protein aggregation or bacterial contamination
Compounded formulations
Non-FDA approved compounded versions may have quality/potency variability
What to Expect
- Week 1-2: IGF-1 levels begin to rise, possible mild water retention or joint discomfort
- Week 4-6: Early metabolic changes, slight improvements in energy and sleep quality
- Week 8-12: Visible visceral fat reduction begins, waist circumference may decrease
- Week 12-26: Peak effects achieved with significant body composition improvements
Side Effects & Safety
- Monitor blood glucose regularly - 3.3-fold increased diabetes risk documented
- IGF-1 levels should be checked monthly - 47% exceed normal range at 26 weeks
- Contraindicated in active malignancy or pituitary disorders
- Common side effects include injection site reactions (17%) and joint pain (13%)
References
Cardiovascular Risk Assessment (2025)
Recent meta-analysis demonstrating cardiovascular risk reduction through improved metabolic parameters
View Study (opens in new tab) →Anti-inflammatory Effects Study (2021)
Comprehensive analysis showing reduced VEGFA, TGFB1, and CSF1 inflammatory markers beyond metabolic effects
View Study (opens in new tab) →NAFLD Treatment Trial (2019)
Landmark study demonstrating significant hepatic fat reduction and prevented fibrosis progression in HIV patients with NAFLD
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia